INTRODUCTION AND OBJECTIVES: To evaluate the significance of contrast-enhanced ultrasound(CEUS) in diagnosis and differential diagnosis of renal cell carcinoma associated with Xp11.2 translocation/TFE3 gene fusions (Xp11.2 RCC) and clear cell renal cell carcinoma (CCRCC).
METHODS: We retrospectively analyzed the conventional ultrasound (CUS) and CEUS data of 15 cases proved to be Xp11.2 RCC and 72 cases proved to be CCRCC by pathology after surgery. RESULTS: Xp11.2 RCC more frequently affected young (32.3AE 12.6 years) women (9/15, 60%) with gross hematuria (7/15, 46.7%), while CCRCC more frequently involved middle-aged (51.0 AE 14.1 years) men (47/72, 65.3%). In CUS, both Xp11.2 RCC and CCRCC tended to be quasiccircular and hypo-echoic. Lesion sizes between Xp11.2 RCC (4.6AE1.6 cm) and CCRCC (5.0AE1.8 cm) were unsignificant difference. In CEUS, the arrival time (AT) and time to peak intensity (TTP) of most Xp11.2 RCCs (12/15, 80%) were slower than adjacent renal cortex, while AT and TTP of most CCRCCs (52/72 80.6%) were faster than adjacent renal cortex. The difference of peak intensity (PI) between Xp11.2 RCC(hypo-enhancement 9/15, 60%) and CCRCC (hyper-enhancement 53/72, 73.6%) were significant. Contrast agent in most CCRCCs (48/72, 66.7%) was rapid-fading, but all of Xp11.2 RCCs were rapid-fading, there was significant difference between them.
CONCLUSIONS: CEUS provide a new and effective method in diagnosis of Xp11.2 RCC. CEUS are useful in differential diagnosis of Xp11.2 RCC with CCRCC. Vol. 197, No. 4S, Supplement, Monday, May 15, 2017 THE JOURNAL OF UROLOGY â e989
